Why are we still doing industrial age drug
Upcoming SlideShare
Loading in...5
×
 

Why are we still doing industrial age drug

on

  • 605 views

 

Statistics

Views

Total Views
605
Views on SlideShare
599
Embed Views
6

Actions

Likes
2
Downloads
2
Comments
0

2 Embeds 6

http://www.linkedin.com 3
https://twitter.com 3

Accessibility

Upload Details

Uploaded via as Adobe PDF

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Processing…
Post Comment
Edit your comment

Why are we still doing industrial age drug Why are we still doing industrial age drug Presentation Transcript

  • Why Are We Still Doing Industrial Age Drug Discovery For Neglected Diseases in The Information Age? Sean Ekins Collaborations In Chemistry, Fuquay Varina, NC
  • Some Technologies change faster than we do
  • But Drug Discovery has not changed much in 40 years
  • Because change happens slowly Drug discovery is a very slow race… that needs a kickstart
  • Still valuing the 70’s BLOCKBUSTER model but its changing And of course no treatments for neglected diseases are blockbusters
  • The Old School vs New School screening • • • New School - Many hurdles before in vivo lots of data Yet HTS started in the 1980’s!! Old school – go in vivo at outset – little data New database technologies work well for New school but ..Old School type data ?
  • Drug Discovery Archeology • Still a heavy emphasis on “testing” “doing “ rather than ‘learning’ • Mining data and historic data will increase in value • Data becomes a repurposing opportunity • How do we position databases for this? • What about neglected diseases?
  • Now neglected diseases has big data too
  • A computational window into data and models Should there be more ?
  • But what about small data? • In some cases its all we have • In vivo data is not high throughput V • Small data builds networks http://smalldatagroup.com/
  • Ponder et al., Pharm Res In Press 2013
  • Big Data: Screening for New Tuberculosis Treatments Tested >300,000 molecules >1500 active and non toxic Tested ~2M Published 177 How many will become a new drug? How do we learn from this big data?
  • Small data: Mouse In vivo model data «Tuberculosis» 333 papers in PubMed «Malaria» 301 papers in PubMed
  • Can combining Big and Small data (in vitro, in vivo) help us find better compounds, faster ? Avoid testing as many molecules
  • In vitro data In vivo data Target data ADME/Tox data & Models Connecting data/tools like a TB Spider Drug-like scaffold creation TB Prediction Tools TB Publications
  • Where are the New TB drugs to be found? In vivo actives (yellow)
  • Optimal Mouse properties Optimal TB entry properties Optimal Human properties
  • Filling the toolbox • Who has the data? • Who has the models? • Who has molecules? Drug Discovery Toolbox
  • Hunting for the in vivo data It’s out there.. be patient
  • TB 30 years with little TB mouse in vivo data
  • MoDELS RESIDE IN PAPERS NOT ACCESSIBLE…THIS IS UNDESIRABLE
  • Hunting High and Low for new molecules to test We need to search sources.. From the Oceans… To the ground To the trees To the air.. And do it virtually
  • Time for the New New School Models replace testing Testing = confirming Predict in vivo and in vitro in parallel MULTIDIMENSIONAL Save resources
  • TO BE CONTINUED…
  • Joel S. Freundlich Antony J. Williams Alex M. Clark